Related Experiment Video
Updated: Oct 12, 2025
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical
Hui Yang1,2,3, Shaoxing Sun1,2,3, Zijie Mei1,2,3
1Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.
Background:
Anlotinib is an oral anti-angiogenesis inhibitor targeting vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors, fibroblast growth factor receptors, etc., and its clinical value in cervical cancer is rarely reported. We designed a retrospective study to evaluate the efficacy and safety of anlotinib in patients with persistent, metastatic, or recurrent cervical cancer who have failed first-line therapy, and compare the efficacy of anlotinib with that of apatinib which targets only VEGFR2 and has shown efficacy in recent studies.
Methods:
Fifty-two patients with persistent, metastatic, or recurrent cervical cancer who failed first-line therapy and administrated anlotinib or apatinib as monotherapy or combination with chemo-, radio- or immunotherapy were included in this study. Among the 52 patients, 20 patients who received anlotinib from January 2019 to August 2020 were defined as anlotinib group, whereas 32 patients who received apatinib from our previous study were selected as apatinib group. The safety, objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were reviewed and recorded.
Results:
The ORR and DCR in patients receiving anlotinib were 25% and 80%, respectively. The median PFS and OS in anlotinib group were significantly longer than those in apatinib group, respectively (PFS: 5 months vs 3 months, p=0.015; OS: 10 months vs 5 months, p=0.008). Moreover, the patients treated with anlotinib had better survival with a significantly lower cumulative incidence of cancer-related death than those treated with apatinib (HR=0.31, 95% CI: 0.13-0.77, p=0.012). The most common adverse effects in the patients treated with anlotinib were hypertension (20%), fatigue (20%), and nausea (15%). No drug-related death occurred.
Conclusion:
Anlotinib showed beneficial efficacy and safety and can be a treatment option for patients with persistent, metastatic, or recurrent cervical cancer who have failed the first-line therapy.
Insights
Anlotinib demonstrates superior efficacy and safety compared to apatinib for advanced cervical cancer patients who have not responded to initial treatments. This oral anti-angiogenesis inhibitor offers improved progression-free and overall survival, establishing it as a viable treatment option.
Area of Science:
- Oncology
- Pharmacology
Background:
- Anlotinib is an oral anti-angiogenesis inhibitor targeting multiple receptor tyrosine kinases.
- Clinical data on anlotinib for cervical cancer remains limited.
- Cervical cancer patients often face limited treatment options after first-line therapy failure.
Purpose of the Study:
- To evaluate the efficacy and safety of anlotinib in patients with persistent, metastatic, or recurrent cervical cancer.
- To compare anlotinib with apatinib, another anti-angiogenesis agent, in this patient population.
Main Methods:
- Retrospective study including 52 patients with advanced cervical cancer who failed first-line therapy.
- Patients received either anlotinib or apatinib as monotherapy or in combination with other treatments.
- Outcomes assessed included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Main Results:
- Anlotinib group showed an ORR of 25% and DCR of 80%.
- Median PFS and OS were significantly longer in the anlotinib group (5 months and 10 months, respectively) compared to the apatinib group (3 months and 5 months).
- Anlotinib treatment resulted in a significantly lower cumulative incidence of cancer-related death.
Conclusions:
- Anlotinib demonstrates beneficial efficacy and safety in patients with advanced cervical cancer post-first-line therapy failure.
- Anlotinib represents a promising treatment option for this patient group.
- Further prospective studies are warranted to confirm these findings.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
